Skip to content

Prediction of survival by physicians and assessment of symptoms in patients with liver, pancreatic and gallbladder cancers in a palliative care setting

Clinical prognostication and symptom assessment in patients with metastatic hepatopancreaticobiliary cancers referred for specialist palliative care in a tertiary care cancer setting: A prospective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/08/044932
Enrollment
100
Registered
2022-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C221- Intrahepatic bile duct carcinoma Health Condition 2: C220- Liver cell carcinoma Health Condition 3: C249- Malignant neoplasm of biliary tract, unspecified Health Condition 4: C251- Malignant neoplasm of body of pancreas Health Condition 5: C23- Malignant neoplasm of gallbladder Health Condition 6: C250- Malignant neoplasm of head of pancreas Health Condition 7: C229- Malignant neoplasm of liver, not specified as primary or secondary Health Condition 8: C228- Mali

Interventions

Intervention1: NIL: NIL

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age >18 years. 2) Able to give informed consent. 3) Able to communicate in Hindi/English/Marathi/Bengali. 4) Eastern Cooperative Oncology Group(ECOG) score �1.

Exclusion criteria

Exclusion criteria: 1)Patient planned for any disease directed treatment. 2)Patients with any pre-existing psychiatric disorder or intellectual disability.

Design outcomes

Primary

MeasureTime frame
Comparing Clinician predicted survival (CPS) versus Actual survival (AS) at the end of 90 days by calculating difference in days (temporal prediction), assessing percentage chance of survival (probabilistic prediction) at 48 hrs,7 days,30 days,60 days and 90 days and surprise question approach.Timepoint: Baseline evaluation

Secondary

MeasureTime frame
Comparing predicted survival by PPI with CPS.Timepoint: Baseline evaluation;Comparing temporal prediction versus probabilistic prediction versus surprise question approach. Timepoint: Baseline evaluation;Patient or caregiver reported burden on Edmonton Symptom Assessment System- revised (ESAS-r).Timepoint: Baseline evaluation, 15 days, 30 days, 60 days, 90 days.;Using PPI as a prognostic tool and comparing it with Actual survival (AS).Timepoint: Baseline evaluation and at end of 90 days.

Countries

India

Contacts

Public ContactDr Jayita K Deodhar

Tata Memorial Hopsital

jukd2000@yahoo.co.uk

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026